Posted by Rick on November 11, 1999, at 15:29:02
In reply to Same Study, But , Yes, You are Missing the Point, posted by JohnB on November 11, 1999, at 8:53:55
John B.
That would make sense. But I'm surprised neither the abstract nor the press release mentioned this key finding nor the planned follow-up.
Since you must have a copy of the full report, I have a few questions: Did the complete study break out response rates by dosage level? Were side effects worse at the higher levels? How long did effects take to kick in at the mega-doses?
Thanks,
Rick
> Rick, yes, I think you are missing the point. The study was conducted with dosages ranging from 1800 mg/day to 3600 mg/day. So, the overall efficacy ratings are an average of patient response at the different dosages. 1800 mg/day is supposed to be sub-therapeutic, as is 2400 mg/day, as far as social phobia is concerned. 3600mg/day to 4800 mg/day are where the results are suppose to kick in. Discounting the patients at dosages under 3600 mg/day, you can easily estimate that the response for the few at the higher dosages was SIGNIFICANTLY higher than a 30% response rate.
>
> Parke-Davis is planning a follow-up study at the higher dosages, as indicated at the end of their study report.
>
> JohnB
poster:Rick
thread:14991
URL: http://www.dr-bob.org/babble/19991108/msgs/15021.html